Antigens Patents (Class 435/69.3)
  • Patent number: 10196089
    Abstract: A method of controlling a backing system for a vehicle and trailer assembly comprises initiating a backing system mode with an electronic control unit (ECU) for the backing system when a start system input is received from a control device. At least one input is received by the ECU from the control device which includes information about a desired vehicle action. The ECU interprets from the at least one input the desired vehicle action and calculates a required vehicle response to achieve the desired vehicle action. The ECU then sends a request to at least one vehicle system to perform the calculated vehicle response.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 5, 2019
    Assignee: Continental Automotive Systems, Inc.
    Inventors: Brandon Herzog, Andre Payant, Jeremy J. McClain, Ibro Muharemovic, Graham Fletcher, Jeffrey Weber, Dominik Froehlich, Steffen Linkenbach, David Agnew
  • Patent number: 10125373
    Abstract: A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures to optimize the expression is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of the multi-replicon single vector system for producing Rituximab in plant cells.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: November 13, 2018
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Hugh Mason, Charles Arntzen, Sun Hee Rosenthal, Sean Winkle, Andrew Diamos
  • Patent number: 10047149
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: August 14, 2018
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carla Emolo, Andrea DeDent
  • Patent number: 9968668
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 15, 2018
    Assignee: The University of Chicago
    Inventors: Molly McAdow, Andrea Dedent, Alice Cheng, Carla Emolo, Dominique Missiakas, Olaf Schneewind
  • Patent number: 9963698
    Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 8, 2018
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
  • Patent number: 9833511
    Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: December 5, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
  • Patent number: 9821048
    Abstract: The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ.ID.No. 1, whereby such region is defined by (a) amino acid positions 150 to 200 of the amino acid sequence according to SEQ.ID.No.1, or (b) amino acid positions 410 to 480 of the amino acid sequence according to SEQ.ID.No.1, and whereby the polypeptide is suitable to elicit an immune response which is capable of inhibiting the catalytic activity of HPGGT.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 21, 2017
    Assignee: IMEVAX GMBH
    Inventors: Markus Gerhard, Christian Schmees, Christian Prinz
  • Patent number: 9770517
    Abstract: Described herein are compositions and methods of use of antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. More preferably, the antibody is humanized. Preferably the drug is SN-38, pro-2-pyrrolinodoxorubicin, paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD or MMAF. The compositions and methods are of use to treat Trop-2 expressing cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer. Preferably, the cancer is one that is resistant to one or more standard cancer therapies. More preferably, the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells, but administration of the anti-Trop-2 ADC to human cancer patients at a therapeutically effective dosage produces only limited toxicity.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: September 26, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Patent number: 9701738
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria, in certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 11, 2017
    Assignee: The University of Chicago
    Inventors: Molly McAdow, Carla Emolo, Dominique Missiakas, Olaf Schneewind
  • Patent number: 9556281
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 31, 2017
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carla Emolo, Andrea DeDent
  • Patent number: 9494608
    Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: November 15, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
  • Patent number: 9463227
    Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 11, 2016
    Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: John Rothman, Anu Wallecha, Reshma Singh, Donald A. Harn, Jr., Yvonne Paterson
  • Patent number: 9402890
    Abstract: The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 2, 2016
    Assignee: UAB Research Foundation
    Inventors: Ilya Frolov, Elena Frolova
  • Patent number: 9295720
    Abstract: The invention relates to treatment of prostate cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of a prostatic tumor cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment of prostate cancer. Said immunogenic polypeptides are provided by the zona pellucida (ZP) (glyco)proteins. ZP (glyco)proteins and fragments thereof that can induce a CD8+ and/or CD4+ T cell response as well as nucleic acid sequences encoding them can suitably be used in the present immunotherapeutic strategies.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: March 29, 2016
    Assignee: PANTARHEI BIOSCIENCE B.V.
    Inventor: Herman Jan Tijmen Coelingh Bennink
  • Patent number: 9144607
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 29, 2015
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • Patent number: 9125864
    Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: September 8, 2015
    Assignee: Novartis AG
    Inventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
  • Patent number: 9090676
    Abstract: The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ. ID. No. 1, whereby such region is defined by (a) amino acid positions 150 to 200 of the amino acid sequence according to SEQ. ID. No. 1, or (b) amino acid positions 410 to 480 of the amino acid sequence according to SEQ. ID. No. 1, and whereby the polypeptide is suitable to elicit an immune response which is capable of inhibiting the catalytic activity of HPGGT.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: July 28, 2015
    Assignee: IMEVAX GMBH
    Inventors: Markus Gerhard, Christian Schmees, Christian Prinz
  • Patent number: 9079048
    Abstract: A cosmetic or dermopharmaceutical composition comprising enkephalin-derived peptides of general formula (I) for reducing and/or eliminating facial wrinkles is disclosed. The cosmetic or dermopharmaceutical composition can be applied to the skin, preferably skin of the face, to reduce and/or eliminate facial wrinkles, such facial expression wrinkles. Use of the peptide of general formula (I) in the preparation of a cosmetic or dermopharmaceutical composition for reducing and/or eliminating facial wrinkles is also disclosed.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: July 14, 2015
    Assignee: Lipotec, S.A.
    Inventors: Antonio Vincente Ferrer Montiel, Juan Cebrián Puche, Arturo Puig Montiel
  • Publication number: 20150147347
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Jens FRITSCHE, Toni WEINSCHENK, Steffen WALTER, Peter LEWANDROWSKI, Harpreet SINGH
  • Publication number: 20150140027
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 21, 2015
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Publication number: 20150141616
    Abstract: Intermolecular disulfide stabilized foldon polypeptides are provided.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Yuan Lu, James R. Swartz
  • Publication number: 20150140024
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 21, 2015
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 9034598
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Publication number: 20150132334
    Abstract: Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines.
    Type: Application
    Filed: February 22, 2013
    Publication date: May 14, 2015
    Inventors: John Mekalanos, Marek Basler
  • Publication number: 20150132331
    Abstract: Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 14, 2015
    Inventors: Yuan Lu, James R. Swartz
  • Patent number: 9028844
    Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: May 12, 2015
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
  • Publication number: 20150125478
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 7, 2015
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
  • Publication number: 20150125421
    Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 7, 2015
    Inventor: Mark D. Mannie
  • Publication number: 20150125477
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 3, 2014
    Publication date: May 7, 2015
    Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
  • Publication number: 20150125483
    Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Grl/Ag fusion polypeptides.
    Type: Application
    Filed: May 29, 2012
    Publication date: May 7, 2015
    Applicant: Tetragenetics, Inc.
    Inventors: Theodore G. Clark, Yelena Bisharyan, Ashot Papoyan, Kyle Anderson, Paul Colussi
  • Publication number: 20150110826
    Abstract: The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Applicant: SANOFI VACCINE TECHNOLOGIES, S.A.S.
    Inventors: Anne-Cecile V. BAYNE, James Casey LIPPMEIER, Kirk Emil APT, Ross Eric ZIRKLE
  • Publication number: 20150110836
    Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
    Type: Application
    Filed: May 21, 2013
    Publication date: April 23, 2015
    Inventor: Jacob E. Glanville
  • Publication number: 20150104477
    Abstract: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Christopher Twitty, Erik LeShane, Bernard Fox, Hong-Ming Hu, Guangjie Yu
  • Publication number: 20150104830
    Abstract: The invention provides a process for generating an avian cell line of duck origin by a process comprising: —cultivating embryonic avian cells in cell culture medium, preferably comprising fetal calf serum (FBS) for more than 40 passages while reducing the concentration of FBS to 1-2% vol/vol FBS, —transferring passaged cells into cell culture medium having 0% FBS, —resulting in the generation of a non-embryonic avian cell line suitable for non-adherent growth, i.e. for growth in suspended culture.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 16, 2015
    Inventors: Manfred Wirth, Lijing Sun, Zhiguo Su, Roland Riebe, Jaeger Volker, Nadine Konisch
  • Publication number: 20150104480
    Abstract: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a structural virus protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 16, 2015
    Inventors: Marc-Andre D'Aoust, Manon Couture, Louis-Philippe Vezina
  • Publication number: 20150104475
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Application
    Filed: July 5, 2013
    Publication date: April 16, 2015
    Applicant: The Ohio State University
    Inventor: Daral John Jackwood
  • Patent number: 8999347
    Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterized in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: April 7, 2015
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Joseph D Cohen, Martine Marchand
  • Publication number: 20150094226
    Abstract: The present invention provides detailed three-dimensional structural information for the complex formed by the Nef protein and the sdAb19 antibody fragment. In addition, the present invention also provides residues which mediate the interaction between the Nef protein and the sdAb19 antibody fragment. The present invention also provides methods for identifying compounds modulating the interaction of the Nef protein and the sdAb19 antibody.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 2, 2015
    Inventors: Serge BENICHOU, Matthias GEYER, Sebastian LULF
  • Publication number: 20150093404
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 2, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Luis Alejandro HERNANDEZ, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN, Gregory HAIWICK
  • Publication number: 20150093415
    Abstract: The present invention provides a preparation method of an antigen composition. The preparation method comprises the following steps: (1) obtaining a tumor antigen protein; (2) making the tumor antigen protein into contact with an immature dendritic cell; (3) inducing the immature dendritic cell in contact with the tumor antigen into a mature dendritic cell; and (4) separating a cell vesicle of the mature dendritic cell. The present invention further provides an antigen composition obtained through the preparation method and the application thereof in preparing a tumor vaccine.
    Type: Application
    Filed: February 4, 2013
    Publication date: April 2, 2015
    Applicant: National Center for Nanoscience and Technology
    Inventors: Guangjun Nie, Xin Tian, Motao Zhu
  • Publication number: 20150093408
    Abstract: The present invention relates to a Lyme disease vaccine, a genetic construct, recombinant protein, method for genetic construct design, method for vaccine delivery, method for recombinant proteins delivery, use of recombinant proteins in the production of Lyme disease vaccine. In particular, the method concerns the use of TROSPA and TROSPA-Salp15 recombinant proteins derived from castor bean tick (Ixodes riccinus) as a component of Lyme disease vaccine for animals. The antibodies present in blood of an immunized vertebrate directed against the TROSPA proteins considerably reduce the chance of infecting new ticks by blocking or hindering the interaction of TROSPA protein with OspA protein of Borrelia burgdorferi sensu lato. The interaction is crucial in the process of the spirochete entering a tick.
    Type: Application
    Filed: October 21, 2013
    Publication date: April 2, 2015
    Inventors: Anna Urbanowicz, Marek Figlerowicz, Dominik Lewandowski
  • Patent number: 8992935
    Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 31, 2015
    Assignee: Ondek Pty. Ltd.
    Inventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
  • Publication number: 20150086561
    Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Robert STEPHENSON, Reyna J. SIMON, Omar NOURZAIE
  • Publication number: 20150086589
    Abstract: The present invention relates to novel virus-like particles (VLPs) comprising a matrix protein derived from a first plant enveloped virus and a surface polypeptide. The surface polypeptide comprises (a) a surface exposed portion derived from a target polypeptide (b) a transmembrane domain, and (c) a cytosolic tail derived from a transmembrane (e.g., glycoprotein) of a second plant enveloped virus. The target polypeptide may be antigenic or therapeutic. The first and the second plant enveloped viruses may be the same. Either plant enveloped virus may be a plant rhabdovirus. Also provided are methods of making and using the VLPs.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Applicant: FRAUNHOFER USA Inc.
    Inventors: Alexei Prokhnevsky, Vidadi Yusibov
  • Publication number: 20150086582
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Application
    Filed: August 1, 2014
    Publication date: March 26, 2015
    Inventors: Claire FRASER, Cesira GALEOTTI, Guido GRANDI, Erin HICKEY, Vega MASIGNANI, Marirosa MORA, Jeremy PETERSEN, Mariagrazia PIZZA, Rino RAPPUOLI, Giulio RATTI, Vincenzo SCARLATO, Maria SCARSELLI, Herve TETTELIN, J. Craig VENTER
  • Publication number: 20150086588
    Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (HN) gene and the large RNA polymerase protein (L) gene of the PIV5 genome. In some embodiments, the heterologous nucleotide sequence is inserted between the small hydrophobic protein (SH) gene and the hemagglutinin-neuroaminidase (HN) gene of the PIV 5 genome.
    Type: Application
    Filed: January 24, 2013
    Publication date: March 26, 2015
    Inventor: Biao He
  • Patent number: 8986702
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: March 24, 2015
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Patent number: 8986704
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 24, 2015
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
  • Publication number: 20150079124
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Application
    Filed: August 1, 2014
    Publication date: March 19, 2015
    Inventors: Claire FRASER, Cesira GALEOTTI, Guido GRANDI, Erin HICKEY, Vega MASIGNANI, Marirosa MORA, Jeremy PETERSEN, Mariagrazia PIZZA, Rino RAPPUOLI, Giulio RATTI, Vincenzo SCARLATO, Maria SCARSELLI, Herve TETTELIN, J. Craig VENTER
  • Publication number: 20150079120
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Helmut FIEBIG, Andreas NANDY, Roland SUCK, Oliver CROMWELL, Arnd PETERSEN, Wolf-Meinhard BECKER